BioSpace News Archive

Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research Annual Meeting, which is taking place both virtually and in-person at the Ernest N.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

HOOKIPA Pharma Inc. announced that preclinical, translational, and clinical biomarker data from its oncology pipeline have been selected for four poster presentations at the 2022 American Association for Cancer Research Annual Meeting, taking place April 8-13.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the data from its oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, Louisiana.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that it will present preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor, KB-0742, in four poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces that the company will be presenting the first data for BI-1607 at the forthcoming annual meeting of the American Association for Cancer Research in April 2022.

7 Hills Pharma LLC (“7 Hills” or “7HP”), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to 7HP349, 7HP’s lead clinical-stage immunostimulant, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.